Track your baseline metricsweight, body composition if available, performance markersand reassess after 3 months
According to a recently released approval letter, the FDA has instructed Eli Lilly to study potential risks associated with Foundayo, especially those related to the heart and liver
Inactivation of peroxiredoxin I by phosphorylation allows localized H2O2 accumulation for cell signaling
If you are considering GLP-1 therapy, focus on evidence-based dosing, medication tolerance, and lifestyle factors with your provider
Routine consultation with your healthcare provider is appropriate when: Taste changes lead to significant unintentional weight loss beyond treatment goals Nutritional intake becomes severely restricted, raising concerns about deficiencies Taste alterations persist beyond 8-12 weeks without improvement Quality of life is substantially impacted by food aversions or taste disturbances New or worsening symptoms develop, such as persistent metallic taste with other concerning features Your provider can assess whether taste changes represent expected treatment effects or require investigation for alternative causes
